. 2022 Nov 15;12(11):e061008. doi: 10.1136/bmjopen-2022-061008

Table 1.

Characteristics of the included studies

First author	Year	Country	Level of evidence	No of participants (M/F)		Intervention method in CG	Age, years (mean or mean±SD)		BMI, kg/m² (mean or mean±SD)		Follow-up period, months	Stem cell source	K-L grade
First author	Year	Country	Level of evidence	MSCs+PRP	CG	Intervention method in CG	MSCs+PRP	CG	MSCs+PRP	CG	Follow-up period, months	Stem cell source	K-L grade
Bastos²⁴	2019	Portugal	II	14 (5/9)	16 (10/6)	MSCs	60.8±9.9	55.7±7.8	28.9±4.9	30.6±4.5	12	Bone marrow	1–4
Lamo-Espinosa²⁵	2020	Spain	I	24 (17/7)	26 (16/10)	PRP	56	54.6	27	25.3	12	Bone marrow	2–4
Bastos²⁶	2018	Portugal	II	9 (4/5)	9 (5/4)	MSCs	60.4±11.3	54.7±7.2	NR	NR	12	Bone marrow	2–4
Hou²⁷	2016	China	I	92 (40/52)	88 (38/50)	HA	57±8.3	55±9.2	NR	NR	6	Bone marrow	NR
Cheng²⁸	2019	China	I	20 (8/12)	20 (9/11)	HA	54.6±6.2	52.9±5.3	22.1±1.6	21.5±1.5	6	Bone marrow	1–3
Ha²⁹	2018	China	I	45 (15/30)	44 (14/30) 43 (12/31) 43 (11/32)	PRP MSCs HA	56.8±6.1	55.6±3.6 57±3.2 56.2±6.7	25.5±2	25.4±0.8 25.8±3.3 24.9±1.6	12	Umbilical cord	1–3

BMI, body mass index; CG, control group; F, female; HA, hyaluronic acid; KL, Kellgren-Lawrence; M, male; MSCs, mesenchymal stem cells; NR, not reported; PRP, platelet-rich plasma.